- Home
- ONL vs ABEO Comparison
ONL vs ABEO Comparison
Compare ONL & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- ABEO
- Stock Information
- Founded
- ONL 2021
- ABEO N/A
- Country
- ONL United States
- ABEO United States
- Employees
- ONL N/A
- ABEO N/A
- Industry
- ONL Real Estate Investment Trusts
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- ABEO Health Care
- Exchange
- ONL Nasdaq
- ABEO Nasdaq
- Market Cap
- ONL 210.4M
- ABEO 247.8M
- IPO Year
- ONL N/A
- ABEO 1980
- Fundamental
- Price
- ONL $3.88
- ABEO $5.70
- Analyst Decision
- ONL Hold
- ABEO Strong Buy
- Analyst Count
- ONL 1
- ABEO 3
- Target Price
- ONL N/A
- ABEO $18.00
- AVG Volume (30 Days)
- ONL 310.7K
- ABEO 229.2K
- Earning Date
- ONL 11-07-2024
- ABEO 11-14-2024
- Dividend Yield
- ONL 10.39%
- ABEO N/A
- EPS Growth
- ONL N/A
- ABEO N/A
- EPS
- ONL N/A
- ABEO N/A
- Revenue
- ONL $169,644,000.00
- ABEO N/A
- Revenue This Year
- ONL N/A
- ABEO N/A
- Revenue Next Year
- ONL N/A
- ABEO $18,714.71
- P/E Ratio
- ONL N/A
- ABEO N/A
- Revenue Growth
- ONL N/A
- ABEO 147.52
- 52 Week Low
- ONL $3.01
- ABEO $3.05
- 52 Week High
- ONL $6.17
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- ONL 40.57
- ABEO 34.30
- Support Level
- ONL $3.75
- ABEO $5.45
- Resistance Level
- ONL $4.11
- ABEO $6.04
- Average True Range (ATR)
- ONL 0.11
- ABEO 0.19
- MACD
- ONL -0.04
- ABEO -0.04
- Stochastic Oscillator
- ONL 18.14
- ABEO 19.47
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.